Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Lenacapavir-Containing Antiretroviral Therapy in the OPERA Cohort: Patterns of Use and Treatment Outcomes.
Journal: AIDS patient care and STDs
Published: March 28, 2026
Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study.
Journal: Infectious diseases and therapy
Published: February 05, 2026
Comparable real-world effectiveness between switches to cabotegravir + rilpivirine long-acting or modern daily oral regimens in the United States: an OPERA cohort study.
Journal: Journal of the International AIDS Society
Published: May 27, 2025
Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study.
Journal: AIDS research and therapy
Published: May 05, 2025
Suppressed switch to Bictegravir/emtricitabine/tenofovir alafenamide compared with dolutegravir/lamivudine: Real-world evidence from the OPERA cohort.
Journal: HIV medicine
Published: March 18, 2025
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
Journal: Infectious diseases and therapy
Published: August 28, 2023
Immune response to ART initiation in advanced HIV infection.
Journal: HIV medicine
Published: December 19, 2022
Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
Journal: AIDS (London, England)
Published: July 25, 2022
Advanced HIV Infection in Treatment-Naïve Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens.
Journal: Open forum infectious diseases
Published: September 22, 2021
Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
Journal: AIDS reviews
Published: December 05, 2014
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 15, 2014
Last Updated: 09/26/2026